Login
$GALT
$3.02 -$0.03 (0.98%) Live

$GALT 8-K SEC Filings

Filed On Filing
16 Nov 2026 8-K: Results of Operations and Financial Condition

Date of Report (Date of earliest event reported): November 16, 2026

14 Aug 2026 8-K: Results of Operations and Financial Condition

NORCROSS, Ga., August 14, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the th...

04 Aug 2026 8-K: Unregistered Sales of Equity Securities

Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock

23 Jun 2026 8-K: Regulation FD Disclosure

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

15 May 2026 8-K: Results of Operations and Financial Condition

NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three...

31 Mar 2026 8-K: Results of Operations and Financial Condition

NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the yea...

17 Mar 2026 8-K: Departure/Election of Directors or Officers; Compensation

Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.

21 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

12 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

19 Dec 2025 8-K: Entry into a Material Definitive Agreement

This letter agreement supplements that certain Line of Credit Agreement, dated as of July 25 2022, the (“Line of Credit Agreement”), that certain Supplemental Line of Credit Letter Agreement, dated as of March 29, 2024, (the “Supplementa...

08 Dec 2025 8-K: Submission of Matters to a Vote of Security Holders

At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company’s directors that had been nominated to serve until the next annual meeting or until their successors are ele...

03 Dec 2025 8-K: Regulation FD Disclosure

Since I became President and CEO of Galectin Therapeutics, I can honestly say that I have never been as excited as I am today, nor have I had the luxury of sharing such an extensive amount of meaningful information. As I am writing this ...

14 Nov 2025 8-K: Results of Operations and Financial Condition

NORCROSS, Ga., November 14, 2025 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the ...

10 Nov 2025 8-K: Regulation FD Disclosure

Forward-Looking Statements This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events...

08 Sep 2025 8-K: Regulation FD Disclosure

2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial perf...

14 Aug 2025 8-K: Results of Operations and Financial Condition

NORCROSS, Ga., August 14, 2025 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the th...

09 Jul 2025 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation

This letter agreement supplements that certain Line of Credit Agreement, dated as of July 25 2022, the (“Line of Credit Agreement”), that certain Supplemental Line of Credit Letter Agreement, dated as of March 29, 2024, (the “Supplementa...

16 Jun 2025 8-K: Regulation FD Disclosure

Belapectin for MASH Cirrhosis and Portal Hypertension June 2025

15 May 2025 8-K: Results of Operations and Financial Condition

NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three...

12 May 2025 8-K: Regulation FD Disclosure; Other Events

2 This presentation contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial perf...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support